ICU Medical Q2 Revenue Dips Amid Rising Costs
Ticker: ICUI · Form: 10-Q · Filed: Aug 7, 2025 · CIK: 883984
| Field | Detail |
|---|---|
| Company | Icu Medical Inc/De (ICUI) |
| Form Type | 10-Q |
| Filed Date | Aug 7, 2025 |
| Risk Level | medium |
| Sentiment | bearish |
Sentiment: bearish
Topics: Medical Devices, Healthcare, Earnings, Revenue Decline, Cost of Goods Sold, 10-Q Analysis, Q2 2025
Related Tickers: ICUI, BDX, BAX
TL;DR
**ICUI's Q2 revenue dip and rising costs are a red flag; I'm bearish on short-term profitability.**
AI Summary
ICU Medical Inc./DE reported a mixed financial performance for the second quarter ended June 30, 2025. Revenue from contracts with customers for the three months ended June 30, 2025, was $285.5 million, a slight decrease from $290.1 million in the same period of 2024. For the six months ended June 30, 2025, revenue was $570.2 million, compared to $578.9 million in the prior year. The cost of revenue for the quarter increased to $180.2 million from $175.8 million year-over-year, impacting gross margins. Net income figures were not explicitly detailed in the provided snippet, but the changes in revenue and cost of revenue suggest potential pressure on profitability. The company's balance sheet showed common stock shares at 24,300,000 as of June 30, 2025, consistent with December 31, 2024. Strategic outlook remains focused on managing operational costs and maintaining market position in surgical and medical instruments, despite the slight revenue dip. The company continues to navigate a competitive healthcare landscape.
Why It Matters
ICU Medical's slight revenue decline and increased cost of revenue in Q2 2025 signal potential headwinds for investors, suggesting tighter margins and a need for strategic cost management. For employees, this could imply a focus on efficiency and potentially slower growth in certain segments. Customers might see stable product availability but could face future price adjustments if cost pressures persist. In the broader market, this performance reflects the ongoing competitive intensity in the surgical and medical instruments sector, where companies like Becton Dickinson and Baxter International are constantly innovating and vying for market share, putting pressure on ICUI to differentiate.
Risk Assessment
Risk Level: medium — The company experienced a revenue decrease from $290.1 million in Q2 2024 to $285.5 million in Q2 2025, coupled with an increase in cost of revenue from $175.8 million to $180.2 million over the same period. This combination of declining top-line and increasing costs indicates margin pressure, posing a medium risk to future profitability and investor returns.
Analyst Insight
Investors should closely monitor ICU Medical's upcoming earnings calls for detailed explanations of the revenue decline and cost increases, and assess management's strategies to improve profitability. Consider holding off on new investments until there's clear evidence of margin stabilization or growth acceleration.
Financial Highlights
- revenue
- $285.5M
- revenue Growth
- -1.6%
Key Numbers
- $285.5M — Q2 2025 Revenue (Decreased from $290.1M in Q2 2024, indicating a 1.6% decline.)
- $180.2M — Q2 2025 Cost of Revenue (Increased from $175.8M in Q2 2024, putting pressure on gross margins.)
- 24.3M — Common Stock Shares (Consistent as of June 30, 2025, and December 31, 2024.)
- $570.2M — Six-Month 2025 Revenue (Down from $578.9M in the prior year, a 1.5% decrease.)
Key Players & Entities
- ICU MEDICAL INC/DE (company) — filer of 10-Q
- Bloomberg (company) — publisher of analysis
- $285.5 million (dollar_amount) — revenue for Q2 2025
- $290.1 million (dollar_amount) — revenue for Q2 2024
- $570.2 million (dollar_amount) — revenue for six months ended June 30, 2025
- $578.9 million (dollar_amount) — revenue for six months ended June 30, 2024
- $180.2 million (dollar_amount) — cost of revenue for Q2 2025
- $175.8 million (dollar_amount) — cost of revenue for Q2 2024
- 24,300,000 (dollar_amount) — common stock shares as of June 30, 2025
- SEC (regulator) — filing oversight
FAQ
What was ICU Medical's revenue for the second quarter of 2025?
ICU Medical's revenue from contracts with customers for the three months ended June 30, 2025, was $285.5 million, a decrease from $290.1 million in the same period of 2024.
How did ICU Medical's cost of revenue change in Q2 2025?
The cost of revenue for ICU Medical increased to $180.2 million for the three months ended June 30, 2025, compared to $175.8 million for the same period in 2024.
What is the strategic outlook for ICU Medical given the Q2 2025 results?
The strategic outlook for ICU Medical will likely focus on managing operational costs and maintaining market position in surgical and medical instruments to counteract the slight revenue dip and rising cost of revenue.
What are the key risks for ICU Medical investors based on this 10-Q?
Key risks for ICU Medical investors include declining revenue, as seen with the Q2 2025 revenue of $285.5 million compared to $290.1 million in Q2 2024, and increasing cost of revenue, which can compress profit margins.
How does ICU Medical's Q2 2025 performance compare to the previous year?
ICU Medical's Q2 2025 revenue of $285.5 million was lower than the $290.1 million reported in Q2 2024, and the cost of revenue increased from $175.8 million to $180.2 million year-over-year.
What impact might the Q2 2025 results have on ICU Medical's stock?
The Q2 2025 results, showing a revenue decline and increased costs, could put downward pressure on ICU Medical's stock as investors react to potential margin compression and slower growth.
Are there any significant changes in ICU Medical's common stock shares?
No, ICU Medical's common stock shares remained consistent at 24,300,000 as of June 30, 2025, compared to December 31, 2024.
What industry does ICU Medical operate in?
ICU Medical Inc./DE operates in the surgical and medical instruments and apparatus industry, as indicated by its Standard Industrial Classification (SIC) code 3841.
What should investors do with ICU Medical's stock after this filing?
Investors should consider monitoring ICU Medical's future performance closely and potentially deferring new investments until there is a clearer indication of improved revenue growth or cost management strategies.
Where is ICU Medical Inc./DE headquartered?
ICU Medical Inc./DE is headquartered at 951 Calle Amanecer, San Clemente, CA 92763-6212.
Industry Context
ICU Medical Inc./DE operates in the competitive surgical and medical instruments industry. The sector is characterized by continuous innovation, stringent regulatory oversight, and evolving healthcare purchasing dynamics. Companies in this space must balance product development with cost management to maintain market share.
Regulatory Implications
As a medical device company, ICU Medical Inc./DE is subject to rigorous regulatory scrutiny from bodies like the FDA. Compliance with manufacturing standards, product approvals, and post-market surveillance are critical. Any lapses in compliance can lead to significant fines, product recalls, and reputational damage.
What Investors Should Do
- Monitor gross margin trends closely.
- Analyze the drivers of the revenue decline.
- Evaluate the company's cost management initiatives.
Glossary
- Revenue from Contract With Customer Excluding Assessed Tax
- This represents the total revenue recognized by the company from its core business operations, after accounting for any taxes that are collected on behalf of a government entity. (This is the primary measure of the company's sales performance and is used to calculate revenue growth and other key financial ratios.)
- Cost of Revenue
- This includes all direct costs associated with producing the goods or services sold by the company, such as raw materials, direct labor, and manufacturing overhead. (Changes in the cost of revenue directly impact the company's gross profit and overall profitability.)
Year-Over-Year Comparison
Compared to the prior year, ICU Medical Inc./DE reported a slight decrease in revenue for both the second quarter (down 1.6% to $285.5 million) and the first six months (down 1.5% to $570.2 million) of 2025. Concurrently, the cost of revenue saw an increase to $180.2 million for the quarter, indicating pressure on gross margins. The number of common stock shares remained consistent at 24.3 million, suggesting no significant equity dilution or buybacks in the period.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on August 7, 2025 regarding ICU MEDICAL INC/DE (ICUI).